The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. - Test2 - elhamkhani - TriplyDB

The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.

The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.

http://www.wikidata.org/entity/Q35083727

about

Novel therapeutic targets for pancreatic cancer The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas Ral GTPases in tumorigenesis: emerging from the shadows Ral-Arf6 crosstalk regulates Ral dependent exocyst trafficking and anchorage independent growth signalling Discovery and characterization of small molecules that target the GTPase Ral Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks.Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.A Rab10:RalA G protein cascade regulates insulin-stimulated glucose uptake in adipocytes.Oncogenic Ras stimulates Eiger/TNF exocytosis to promote growth.Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers The MEK-ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformation Drugging the undruggable RAS: Mission possible?The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector Phosphorylation by protein kinase Cα regulates RalB small GTPase protein activation, subcellular localization, and effector utilization.RalGPS2 Is Essential for Survival and Cell Cycle Progression of Lung Cancer Cells Independently of Its Established Substrates Ral GTPases.Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.Differential involvement of RalA and RalB in colorectal cancer.Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways.EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer Ubiquitination of Innate Immune Regulator TRAF3 Orchestrates Expulsion of Intracellular Bacteria by Exocyst Complex.Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion.Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).Roles for KRAS in pancreatic tumor development and progression.The biology and clinical development of MEK inhibitors for cancer.Direct Modulation of Small GTPase Activity and Function.Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation.Inhibition of Ral GTPases Using a Stapled Peptide Approach.Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration.Reverse engineering GTPase programming languages with reconstituted signaling networks.Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers.Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C.Breaking up is hard to do: RalA, mitochondrial fission and cancer.A big new job for small GTPases Ral signaling pathway in health and cancer.Plasma membrane phosphatidylinositol 4-phosphate and 4,5-bisphosphate determine the distribution and function of K-Ras4B but not H-Ras proteins.Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers.New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.

P2860

Q24564267-315FE79E-4DCB-4C92-803A-7E6C1ECAACD7 Q27021883-EAB9D67F-6116-478F-BF50-EFF766EA6369 Q28294053-63C2C90F-46F5-45C6-9752-1B53A5818F18 Q30276654-63D13A0A-B0A6-4A4F-8D3B-F57FCB7F9403 Q30366783-397EC1DC-5A71-4BA5-AF9D-391B91A74410 Q30416201-094178ED-EFA2-474D-AB8C-FAD54EEC571C Q33699097-AC19A9E0-8413-4520-B3C6-82D4A4935ED8 Q33971120-F59AA0C4-7A1B-47EC-86FB-F51DB6360F37 Q34504089-6F667841-331F-4C9B-9240-C58E92DD6D03 Q34985765-C8A1D15F-3E00-432C-88EA-B387140DA50B Q35051540-DC3A9277-E9F3-460C-B5C9-B180AFF2AE73 Q35060981-FBCCED73-74E4-42EE-8B86-D564948C1C57 Q35163434-4B9E7E06-1176-41BA-B7D8-69C1B348925B Q35867942-8E07E027-27BB-4D1A-8E83-A9219A3B15B0 Q35922566-7816DD43-917F-4A2E-9694-6B6912477C1C Q36009623-CB310890-4E0D-4EA5-B955-3891161F3D04 Q36050056-2218D91E-AFE0-4D37-83D0-2C1EDEA293F0 Q36129983-D4C52929-73F6-401F-91CC-69DD8ECAC20F Q36180749-78BB72BB-A2B9-4CD3-AEDF-855A4775673B Q36411034-BE603CE2-3031-482F-B62C-4E084822780A Q37143150-50E52CF1-AE10-4B13-8F83-44F004F48260 Q37542817-F315AFBF-1FA7-4165-B77D-C26B497CEE4E Q37640038-4F9502AD-3CDF-44E9-98B6-F77EB4DEA969 Q38046230-DCD8DC1A-ADD5-489F-8C6F-78FDED84EE6D Q38102106-0333A933-C71A-40CC-AD01-6B9177AC174B Q38270129-3B7004F7-416B-4466-A462-38A3B27189C9 Q38608107-0AE201C0-1520-4BBE-850A-FD466CA77F26 Q38614956-6C291793-2264-488E-95C7-7AF507AE41D7 Q38762732-C8A75DBF-DB77-45A7-8CC0-152275CE74B4 Q38868595-469E043D-D6DD-4299-B492-B16D16B45FEE Q39177459-EC550101-D3E8-4C75-940B-CA59BC1C2EF9 Q39809939-9AC7B419-9AC2-490C-93FE-A5C1D4F3B465 Q41081937-AAF0CD21-47A1-42A0-8501-4B776646F690 Q42055537-1E76E5CE-A4ED-4BAC-85E2-3E93C6BE54E4 Q42136455-28E88FD6-92C6-459E-8637-9E99C10A09AE Q42325462-B5685E85-FA50-473B-9040-6D143121223D Q47124416-F8577DB3-2164-40CF-9A0E-3E76F375059E Q47758406-C7160CCB-F6B2-4E15-A773-1A81EE7ED9AB Q48084362-20E99A8A-59FB-49B3-A7A1-6AA00C43093C Q52666594-A966B88D-9BE0-411B-B009-8480E2040BE2

P2860

The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.

http://www.wikidata.org/entity/Q35083727

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The RalGEF-Ral Effector Signal ...... d for Anti-Ras Drug Discovery.

@ast

The RalGEF-Ral Effector Signal ...... d for Anti-Ras Drug Discovery.

@en

type

label

The RalGEF-Ral Effector Signal ...... d for Anti-Ras Drug Discovery.

@ast

The RalGEF-Ral Effector Signal ...... d for Anti-Ras Drug Discovery.

@en

prefLabel

The RalGEF-Ral Effector Signal ...... d for Anti-Ras Drug Discovery.

@ast

The RalGEF-Ral Effector Signal ...... d for Anti-Ras Drug Discovery.

@en

P1433

Q35083727-AC767AE3-39D3-4B54-9E4C-4751FE88C8F6

P1476

Q35083727-01565CBF-1317-4A46-BA6E-E39E0791B1F0

P2093

Q35083727-1C9CB740-6150-4B57-BB08-F7401BF68D5F

Q35083727-690741FD-4BB8-465A-B289-3281F13A23FF

Q35083727-D83A5439-6972-4D68-9D95-8FD13F5C63B9

Q35083727-D876BFF1-878C-4C04-95BF-B20BB7E296C0

Q35083727-DD0FBCCA-3D86-4D24-A96E-C08726C170A9

Q35083727-F81E4375-1427-4527-945A-DF679CB75240

P2860

Q35083727-01AB4F8B-3FAD-4483-8B9F-80CFBE4E1784

Q35083727-01DE337B-0BCF-4166-8FD6-5B06757179B3

Q35083727-02BB98B9-D5DC-4463-860B-406FE31C0A1A

Q35083727-030C67D1-6E2B-4FEF-BE15-5D9438B3C630

Q35083727-066DBE5F-F599-4DDE-BBF4-B2B5770A3DD0

Q35083727-09EFC7A9-33B0-480B-8C6E-E7C855136E02

Q35083727-0D6FBC6E-8E58-4B3F-A68B-073F9DC45DD7

Q35083727-123A4C3D-CFDE-48B4-85FA-C016CE5C30B1

Q35083727-153045E4-4A1E-40F3-9382-A3353D4FBF49

Q35083727-16E4F706-AC0B-45B4-9076-1F7719089A96

P304

Q35083727-96C38127-A1AB-4EB6-86A0-E0AE9FB5DDED

P31

Q35083727-0896A0E4-729D-4FB1-8857-BBBA06C8B4CA

P356

Q35083727-4674C72E-B770-43C2-BF46-6F9D878601EA

P433

Q35083727-28AD62DF-C491-4D69-9A77-34BDA4D0143F

P478

Q35083727-2A91AECC-CD1A-4EFE-9EDD-65D0981F17B3

P577

Q35083727-E0BAAF30-5566-48C9-8B16-01B92135428A

P5875

Q35083727-85139E26-A85A-492C-AF1F-66F316333287

P698

Q35083727-E97F0DA5-88B2-4E40-8C04-065FEDB47CC9

P932

Q35083727-6AF61768-9155-4BF8-902A-C431FFA04FF9

P356

1947601911407329

P1433

P1476

The RalGEF-Ral Effector Signal ...... d for Anti-Ras Drug Discovery.

@en

P2093

Channing J Der

http://www.w3.org/2001/XMLSchema#string

David J Reiner

http://www.w3.org/2001/XMLSchema#string

Jeran K Stratford

http://www.w3.org/2001/XMLSchema#string

Nicole F Neel

http://www.w3.org/2001/XMLSchema#string

Tanya P Zand

http://www.w3.org/2001/XMLSchema#string

Timothy D Martin

http://www.w3.org/2001/XMLSchema#string

P2860

RalA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling

The small GTPase RalA targets filamin to induce filopodia

Identification and characterization of a new family of guanine nucleotide exchange factors for the ras-related GTPase Ral

Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin

Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth

Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity

The tumor suppressor PP2A Abeta regulates the RalA GTPase

Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator

Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer

Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral

P304

275-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1947601911407329

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51511928

http://www.w3.org/2001/XMLSchema#string

P698

21779498

http://www.w3.org/2001/XMLSchema#string

P932

3128631

http://www.w3.org/2001/XMLSchema#string